Overview

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with surufatinib and tislelizumab in the first line treatment of patients with unresectable or metastatic biliary tract cancer

Phase:

Phase 2

Details

Lead Sponsor:

Wuhan Union Hospital, China

Treatments:

Tislelizumab